Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 5,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Cancer Clear all

Conditions: Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma
Interventions: CAR-GPC3 T Cells; Biological
Lead sponsor: Sotio Biotech Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2042
U.S. locations: 5
States / cities: Newport Beach, California • Dallas, Texas • Houston, Texas + 2 more

Conditions: Lung Neoplasms
Interventions: Indocyanine Green; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer, Melanoma
Interventions: IMM60, Pembrolizumab; Drug
Lead sponsor: iOx Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Advanced Solid Tumors
Interventions: AMG 355, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Duarte, California • Merriam, Kansas • Boston, Massachusetts + 3 more

Conditions: Tumors Characterized by Genetic Abnormalities of ALK
Interventions: LDK378; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more

Conditions: Neoplasms
Interventions: OTL38; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Extensive Stage Small Cell Lung Cancer, Healthy, no Evidence of Disease, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: exercise intervention, standard follow-up care, quality-of-life assessment, laboratory biomarker analysis; Behavioral · Procedure · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Lung Cancer
Interventions: panitumumab, carboplatin, paclitaxel, surgery; Drug · Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 31
States / cities: Carmichael, California • Sacramento, California • Colorado Springs, Colorado + 24 more

Conditions: Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Lucanix™, Placebo Comparator; Biological · Other
Lead sponsor: NovaRx Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 53
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more

Conditions: Lung Cancer
Interventions: epothilone D; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Carcinoma, Non-Small -Cell Lung
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, End-stage Renal Disease, End-stage Liver Disease, Dementia
Interventions: Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement, High patient engagement; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 2,859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • West Los Angeles, California • Aurora, Colorado

Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Malignant Mesothelioma
Interventions: semaxanib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 10
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more

Conditions: Melanoma, Lung Cancer
Interventions: MK-3475, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-Squamous Non-small Cell Lung Cancer
Interventions: AK112 Injection, Placebo Injection; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Bakersfield, California • La Jolla, California • Los Angeles, California + 35 more

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: bioelectric impedance analysis; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Tyrosine Kinase Inhibitor, Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA], Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]; Biological · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Lone Tree, Colorado

Conditions: COVID-19, COVID19, Sars-CoV2, SARS-Cov-2
Interventions: Hydroxychloroquine, Placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Interventions: Lorlatinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 49
States / cities: Sedona, Arizona • Huntington Beach, California • Irvine, California + 30 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Aurora, Colorado • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Breast Carcinoma, Lung Carcinoma
Interventions: Health Education, Health Promotion and Education, Patient Navigation, Survey Administration; Behavioral · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure, Computed Tomography, Positron Emission Tomography; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Lung Cancer, Single Primary Lung Cancer, Second Primary Lung Cancer
Interventions: Blood draw and Questionnaires; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2023
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green

IMM60 and Pembrolizumab in Melanoma and NSCLC

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Intraoperative Imaging of Pulmonary Nodules by OTL38

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy

Analysis of Brain Metastasis in Patients With Lung Cancer

Goals of Care Conversations Study

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

SU5416 in Treating Patients With Malignant Mesothelioma

Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

Phase III Study of AK112 for NSCLC Patients

Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

DNA Repair and Genetic Susceptibility to Lung Cancer